Form 8-K - Current report:
SEC Accession No. 0001437749-25-001569
Filing Date
2025-01-22
Accepted
2025-01-22 16:32:42
Documents
15
Period of Report
2025-01-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K nrxp20250122_8k.htm   iXBRL 8-K 33390
2 EXHIBIT 99.1 ex_768584.htm EX-99.1 9501
  Complete submission text file 0001437749-25-001569.txt   200676

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nrxp-20250115.xsd EX-101.SCH 3911
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE nrxp-20250115_def.xml EX-101.DEF 13856
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE nrxp-20250115_lab.xml EX-101.LAB 18278
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nrxp-20250115_pre.xml EX-101.PRE 13888
17 EXTRACTED XBRL INSTANCE DOCUMENT nrxp20250122_8k_htm.xml XML 4969
Mailing Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801
Business Address 1201 ORANGE STREET SUITE 600 WILMINGTON DE 19801 484-254-6134
NRX Pharmaceuticals, Inc. (Filer) CIK: 0001719406 (see all company filings)

IRS No.: 822844431 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38302 | Film No.: 25546339
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)